Guardant Health, Inc. (GH) Stock Price & Analysis
Guardant Health, Inc. (GH) rose 4.19% to USD 130.12 as of June 10, 2026 at 01:54 UTC, according to Nexqual real-time market data.
GH last closed at USD 124.89; the session ranged USD 122.76–130.36 on volume of 2,258,249 shares. Market capitalization is $17.25B, with a 52-week range of USD 40.35–134.28 (NMS). Source: Nexqual, June 10, 2026 at 01:54 UTC.
Key Statistics (as of June 10, 2026 at 01:54 UTC)
| Price | USD 130.12 |
|---|---|
| Change | ▲ 4.19% (up) |
| Previous Close | USD 124.89 |
| Open | USD 125.27 |
| Day Range | USD 122.76 – 130.36 |
| 52-Week Range | USD 40.35 – 134.28 |
| Volume | 2,258,249 shares |
| Market Cap | $17.25B |
| Exchange | NMS |
Technical Analysis (GH)
Nexqual's technical model rates GH "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 01:54 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.38 (neutral) |
| vs SMA50 | Above (USD 100.36) |
| MACD | 9.23 (positive) |
Analyst Ratings (GH)
Wall Street analysts rate GH "Strong Buy" based on 22 analysts, with a mean price target of USD 137.09 (range USD 90–190), per Nexqual as of June 10, 2026 at 01:54 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 22 |
| Mean Target | USD 137.09 |
| High Target | USD 190 |
| Low Target | USD 90 |
| Buy / Hold / Sell | 22 / 0 / 1 |
Earnings (GH)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $314.04M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.45 vs est -0.47 ▲ beat |
| 2025-12-31 | USD -0.5 vs est -0.47 ▼ miss |
| 2025-09-30 | USD -0.39 vs est -0.49 ▲ beat |
| 2025-06-30 | USD -0.44 vs est -0.51 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financials & Fundamentals (GH)
| Total Revenue | $1.08B |
|---|---|
| Revenue Growth (YoY) | +48.30% |
| Gross Margin | +64.90% |
| Operating Margin | -40.23% |
| Profit Margin | -40.10% |
| Current Ratio | 4.68 |
| Total Cash | $1.10B |
| Total Debt | $1.70B |
| Free Cash Flow | $-85.45M |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Financial Health Score (GH)
Nexqual rates Guardant Health, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:54 UTC.
| Growth | Strong — Revenue +33% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 65%, operating -40% |
| Balance Sheet | Mixed — $1.10B cash vs $1.70B debt |
| Cash Flow | Weak — FCF negative: -$85M, burning cash |
| Efficiency | Mixed — No data |
Ownership (GH)
| Insider Ownership | +4.03% |
|---|---|
| Institutional Ownership | +105.84% |
| Shares Outstanding | 132.60M |
| Float | 127.82M |
| Short % of Float | +10.38% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
Leadership (GH)
Guardant Health, Inc. is led by Helmy Eltoukhy (age 46), Co-Founder, Co-CEO & Chairman, per Nexqual as of June 10, 2026 at 01:54 UTC.
| Co-Founder, Co-CEO & Chairman | Helmy Eltoukhy (age 46) |
|---|---|
| Co-CEO & Director | AmirAli Talasaz (age 45) |
| Chief Financial Officer | Michael Bell (age 56) |
| Chief Technology Officer | Darya Chudova (age 51) |
| Senior Vice President of Operations | Andy Ament |
Major Backers & Investors (GH)
Notable institutional backers of Guardant Health, Inc. include Price (T.Rowe) Associates Inc, Invesco, Goldman Sachs, according to Nexqual as of June 10, 2026 at 01:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 5.3% |
| Invesco | 3.73% |
| Goldman Sachs | 3.35% |
| Two Sigma Investments, LP | 3.19% |
| FMR, LLC | 3.1% |
| Baillie Gifford | 2.91% |
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 18.05% |
| BlackRock | 10.91% |
| Geode Capital | 2.65% |
Source: Nexqual, June 10, 2026 at 01:54 UTC.
From Guardant Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Building on Guardant Reveal's proven performance in MRD detection, the expanded offering leverages our proprietary epigenomic technology powered by the Smart Platform to predict therapy response across all therapy classes, including immunotherapy and chemotherapy, which most patients with advanced-stage cancer receive at some point during their treatment.
- Smart Platform Our proprietary Smart Platform delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic.
- Our product portfolio is now powered by our Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data, to unlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine.
- Therapy Selection Guardant360 CDx Test We believe our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the FDA, and is the market leading comprehensive liquid biopsy test, based on the number of tests ordered.
Partnerships
- In June 2022, we signed a strategic partnership agreement with Adicon Holdings Limited, or Adicon, a leading independent clinical laboratory company based in China, and in December 2023, the blood-based cancer testing services based on our digital sequencing platform became available at Adicon's testing facility, which offers our industry-leading comprehensive genomic profiling tests to biopharmaceutical companies to advance clinical research and the development of new cancer therapies in China.
- In September 2014, we entered into a supply agreement with Illumina, Inc., or Illumina, for Illumina to provide products and services that can be used for certain research and clinical activities, including certain sequencers, reagents, and other consumables for use with the Illumina sequencers, as well as service contracts for the maintenance and repair of the sequencers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTRA | Natera, Inc. | USD 222.82 | ▲ 3.49% |
| TXG | 10x Genomics, Inc. | USD 30.59 | ▼ 1.45% |
| NVCR | NovoCure Limited | USD 17.24 | ▲ 0.47% |
| TWST | Twist Bioscience Corporation | USD 70.06 | ▲ 1.21% |
| VEEV | Veeva Systems Inc. | USD 167.68 | ▼ 2.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:54 UTC. This page is informational and not investment advice.